SCHEMBL1780302

SCHEMBL1780302

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)cc2NC(=O)c2cc(C)nn2CC)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 2/20 0.35
STING1 Q86WV6 3/20 0.34
PDE7A Q13946 3/20 0.34
F10 P00742 1/20 0.34
INSR P06213 9/20 0.34
ALK Q9UM73 9/20 0.34
IGF1R P08069 3/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
BTK Q06187 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
MCL1 Q07820 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1778749 0.92 INSR (0.35) PDE7AF10INSRALKIGF1R
SCHEMBL1778250 0.89 AURKA (0.45) PDE7AINSRALKIGF1RAURKA
SCHEMBL1780565 0.86 ALDH1A1 (0.40) STING1KDM4ELMNA
SCHEMBL1778870 0.86 CSF1R (0.40) WDR5PDE7AINSRALKIGF1R
SCHEMBL1779266 0.86 WDR5 (0.37) WDR5INSRALKIGF1RAURKA
SCHEMBL1777250 0.86 IGF1R (0.44) WDR5PDE7AINSRALKIGF1R
SCHEMBL1781437 0.85 BTK (0.45) INSRALKIGF1RAURKABTK
SCHEMBL1777894 0.85 ALK (0.43) WDR5PDE7AINSRALKIGF1R
SCHEMBL1777877 0.84 PDE7A (0.43) WDR5PDE7AINSRALKIGF1R
SCHEMBL1781045 0.82 SIRT6 (0.42) WDR5PDE7ABTKLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 WDR5 1060/4885STING1 4621/4885PDE7A 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.